Radboud University Medical Center at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Radboud University Medical Center takes part in 3 sessions at ESMO 2026 in Madrid. Its program centres on advanced prostate cancer, including emerging immune-based therapies and blood tests of circulating tumour DNA that look for DNA-repair and PI3K/AKT gene changes. It also covers a nationwide study of cancer treatment and survival in adults with intellectual disability.

OrganizationESMO 2026 Attendance
radboudumc.nl
Cancer centre & hospital
University medical centre in Nijmegen, Netherlands, combining a university hospital with the medical faculty of Radboud University.
Abstract
Fri Oct 23
14:07–14:12
2220RO - Plasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)
Rapid oral: Genitourinary tumours, prostate, penile and testils
Genitourinary cancersGastrointestinal cancers
Talk
Fri Oct 23
16:35–16:55
Emerging immune-based therapies
Emerging therapeutic strategies in advanced prostate cancer
Genitourinary cancers
Talk
Sun Oct 25
10:45–10:55
CN12 - Cancer treatment and survival in adults with intellectual disability: a nationwide population based cohort study
Equitable health care of underserved population
Nursing & supportive care

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Radboud University Medical Center

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction